Tarlatamab
Checked 2026-09-09
Extensive-stage SCLC after platinum-based chemotherapy
One cycle
every 14 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Tarlatamab Bispecific T-cell engager (DLL3×CD3) | 1 mg day 1, 10 mg day 8 and day 15, then 10 mg every 2 weeks | IV | D1, 8 | inpatient monitoring 22-24 h after the first two doses for cytokine release syndrome |
Cycles
until progression (step-up in cycle 1)
14-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- CRS in about half of patients, mostly grade 1-2; ICANS-like neurotoxicity in about 10%.
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4
Carboplatin + etoposide + atezolizumab (or durvalumab)
Extensive-stage SCLC, first line
every 21 days × 4
Topotecan
Relapsed SCLC; platinum-resistant ovarian or cervical cancer
every 21 days